In recent years, Iranian specialists have achieved significant results in treating complex diseases such as leukaemia, myelodysplastic syndrome and lymphoma.

Other progress, according to ParsToday, a partner of TV BRICS, include multiple myeloma, aplastic anaemia as well as some cancers and congenital diseases through bone marrow transplantation.

A breakthrough moment was the creation by an Iranian company of an innovative cellular preparation designed for patients who have undergone bone marrow transplantation.

This drug significantly reduces the risk of graft-versus-host disease (GVHD), a serious complication after transplantation.

A bone marrow transplant, also known as a stem cell transplant, replaces damaged or diseased bone marrow with healthy blood-forming stem cells, often used to treat blood cancers and other conditions.

The primary goal is to replace unhealthy or non-functioning bone marrow with healthy stem cells that can produce new, healthy blood cells (red blood cells, white blood cells, and platelets).

According to Mostafa Ghanei, Secretary of the Biotechnology Development Headquarters, Iran is one of the leaders in the region in terms of the number and quality of bone marrow transplant operations performed.

Bone marrow transplantation has been practised in Iran for more than 30 years.

About 17,000 successful operations have been performed in the country, which is far ahead of other countries in the region, according to Ali Jafarian, Senior Advisor to the Minister of Health.(NAN/TV BRICS)

Edited by Ismail Abdulaziz